Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations-Reference-Cited by-同舟云学术

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

Published:2008-03-01 Issue:7 Volume:26 Page:1182-1184
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Costa Daniel B.¹,Schumer Susan T.¹,Tenen Daniel G.¹,Kobayashi Susumu¹

Affiliation:

1. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.14.9039

Reference7 articles.

1. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

3. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

4. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

5. Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?;Journal of Clinical Medicine;2023-02-10

2. Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer;Oxidative Medicine and Cellular Longevity;2023-01-31

3. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre;Clinical Oncology;2022-11

4. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review);Oncology Letters;2022-09-26

5. Non-small-cell lung cancer: how to manage EGFR-mutated disease;Drugs in Context;2022-08-03